Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera

New England Journal of Medicine

Volumn 350, Issue 2, 2004, Pages 114-124

  Landolfi, Raffaele ^a,g   Marchioli, Roberto ^b   Kutti, Jack ^c   Gisslinger, Heinz ^d   Tognoni, Gianni ^b   Patrono, Carlo ^e   Barbui, Tiziano ^f  

^a CATHOLIC UNIVERSITY   (Italy)

^b Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF VIENNA   (Austria)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

32 P; ACETYLSALICYLIC ACID; ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSULFAN; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CHLORAMBUCIL; CYTOREDUCTIVE AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYUREA; HYPOCHOLESTEROLEMIC AGENT; NITRIC ACID DERIVATIVE; PIPOBROMAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EPISTAXIS; ERYTHROMELALGIA; FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEMATOMA; HEMATURIA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; THROMBOSIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

ASPIRIN; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; RISK FACTORS; THROMBOSIS;

EID: 0346727336     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035572     Document Type: Article

References (22)

1. Tefferi A. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocytopenia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. Semin Haematol 1999;36:Suppl:3-8.
2. Landolfi R, Marchioli P, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997;78:617-21.
3. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962;172:513-23.
4. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-64.
5. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based in Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.
6. Tartaglia A, Goldberg J, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23:172-6.
7. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
8. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965-71.
9. Gruppo Italiano Studio Policitemia. Low-dose aspirin in polycythaemia vera: a pilot study. Br J Haematol 1997;97:453-6.
10. Landolfi R, Marchioli R, European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Semin Thromb Haemost 1997;23:473-8.
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-83. [Erratum, BMJ 2002;324:141.]
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-83. [Erratum, BMJ 2002;324:141.]
13. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-6.
14. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
15. Thrombosis Prevention Trial: randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:1755-62.
16. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
17. de Gaetano G. Low dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
18. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
19. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:893-9.
20. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990;63:163-8.
21. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
22. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002;99:1144-9.